Stockscreener 앱 받기
14.96
2.71%
0.395
시간 외 거래:
14.82
-0.14
-0.94%
Olema Pharmaceuticals Inc 주식(OLMA)의 최신 뉴스
Jefferies Adjusts Price Target for Olema Pharmaceuticals (OLMA) - GuruFocus
Olema Pharmaceuticals (OLMA) Is Down 6.7% After Posting Wider Losses And Filing New Stock Shelf - simplywall.st
Jefferies initiates Olema Pharmaceuticals stock with buy rating By Investing.com - Investing.com Canada
JP Morgan Raises Price Target for Olema Pharmaceuticals (OLMA) | - GuruFocus
Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Olema Pharmaceuticals (OLMA) Drops 33.4% Over Past Month, Reasons Suggest a Potential Turnaround Ahead - Bitget
Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Olema Pharmaceuticals (OLMA) Receives Updated Price Target by Go - GuruFocus
The Goldman Sachs Group Issues Pessimistic Forecast for Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price - MarketBeat
HC Wainwright Issues Optimistic Outlook for OLMA Earnings - MarketBeat
OLMA: Guggenheim Lowers Price Target While Maintaining Buy Ratin - GuruFocus
Olema Pharmaceuticals (OLMA) Receives Increased Price Target fro - GuruFocus
Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting - Bitget
Lab study: Olema drug duo hits cancer growth and spread genes - Stock Titan
Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS) and Olema Pharmaceuticals (OLMA) - The Globe and Mail
Citigroup Forecasts Strong Price Appreciation for Olema Pharmaceuticals (NASDAQ:OLMA) Stock - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Trading Down 5.2% Following Analyst Downgrade - MarketBeat
OLMA: Guggenheim Lowers Price Target While Maintaining Buy Rating | OLMA Stock News - GuruFocus
Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Cut to $38.00 by Analysts at Guggenheim - MarketBeat
Guggenheim lowers Olema Pharmaceuticals price target on trial timing By Investing.com - Investing.com Canada
Breakout Zone: Should I invest in Olema Pharmaceuticals Inc before earningsWeekly Stock Recap & AI Powered Market Trend Analysis - baoquankhu1.vn
Decoding Olema Pharmaceuticals inc (OLMA): A Strategic SWOT Insi - GuruFocus
Olema Pharmaceuticals (OLMA) Stock Rises 9% After Q4 Earnings Beat - MEXC
Short Covering: Does Olema Pharmaceuticals Inc have pricing powerVolume Spike & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch - The Motley Fool
Biotech shares surge almost 300% as $68.7 million investment backs breast cancer treatment aiming for 2027 debut - Bitget
Olema Oncology Reports 2025 Financial Results and Advances Palazestrant in Phase 3 Breast Cancer Trials - Minichart
Shane W. Kovacs sells 241,999 OLMA shares (NASDAQ: OLMA) for $3.25M - Stock Titan
Olema Pharmaceuticals (OLMA) Stock Jumps 9% Following Fourth Quarter Earnings Surprise - MEXC
[144] Olema Pharmaceuticals, Inc. SEC Filing - Stock Titan
Olema Pharmaceuticals 2025 Annual Report: Pipeline Progress, Risk Factors, and Breast Cancer Therapy Insights - Minichart
Olema Pharmaceuticals (NASDAQ:OLMA) Trading Up 8.5% on Earnings Beat - MarketBeat
Olema Pharmaceuticals delivers Q4 and full-year 2025 financial results and updates on milestones - Traders Union
Olema Pharmaceuticals (OLMA) Reports Q4 Earnings Beat - GuruFocus
Olema Oncology (OLMA) Advances Key Cancer Therapies in 2025 - GuruFocus
Olema Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Olema Pharmaceuticals Inc (OLMA) announced that patient recruitment for the Phase 1 clinical study of its candidate drug OP-3136 is underway. - Bitget
854,000 Shares in Olema Pharmaceuticals, Inc. $OLMA Acquired by Kingdon Capital Management L.L.C. - MarketBeat
Olema Oncology reports Q4 EPS (50c), consensus (53c) - TipRanks
Olema Pharmaceuticals (NASDAQ:OLMA) Posts Earnings Results - MarketBeat
Olema 10-K: $0 Revenue, $(1.87) EPS and $(162.5)M Net Loss - TradingView
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results - The Manila Times
Oncology drug developer Olema Pharmaceuticals' Q4 net loss widens on higher R&D costs - TradingView
Olema Pharmaceuticals (NASDAQ: OLMA) outlines late-stage breast cancer drug pipeline - Stock Titan
HighVista Strategies LLC Acquires 158,749 Shares of Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Oncology (NASDAQ: OLMA) boosts cash as 2025 loss widens on R&D - Stock Titan
BRIEF-Olema Pharmaceuticals Q4 Net Income USD -46.061 Million - TradingView
Breast cancer drug developer Olema amasses $505M cash as 2025 loss widens - Stock Titan
Guggenheim Initiates Coverage of Olema Pharmaceuticals (OLMA) with Buy Recommendation - MSN
OLMA Should I Buy - Intellectia AI
Pier Capital LLC Has $5.13 Million Holdings in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Assessing Olema Pharmaceuticals (OLMA) Valuation After Breast Cancer Trial Setback Hits Sector Sentiment - Sahm
A Look At Olema Pharmaceuticals (OLMA) Valuation After Roche Breast Cancer Trial Setback And Share Price Pullback - Yahoo Finance
HC Wainwright Has Negative Forecast for OLMA FY2029 Earnings - MarketBeat
Momentum Shift: Will Olema Pharmaceuticals Inc outperform its industry peersMarket Trend Review & Weekly Top Gainers Trade List - baoquankhu1.vn
Olema Pharmaceuticals inc (OLMA) Stock Price, Quote, News & History - Benzinga
Insider sales at OLMA (NASDAQ: OLMA) include 241,999-share block in March - Stock Titan
What's Going On With Olema Pharmaceuticals Stock On Wednesday? - Benzinga
Does Olema Pharmaceuticals (OLMA) Still Stand Apart After Roche’s Breast Cancer Trial Setback? - Sahm
Dow Tumbles Over 600 Points; Korn Ferry Posts Upbeat Earnings - Sahm
Shane Kovacs sells 241,999 shares; OLMA (NASDAQ: OLMA) Form 144 filing - Stock Titan
H.C. Wainwright does not see direct read from Roche miss to Olema’s OPERA-02 - The Globe and Mail
Olema Pharmaceuticals (OLMA) to Release Quarterly Earnings on Tuesday - MarketBeat
Oppenheimer, Cowen, H.C. Wainwright Maintain Buy/Outperform on OLMA March 2026 - Meyka
1.20%
0.06%
자본화:
|
볼륨(24시간):